Skip to main content
Year archive

Active Biotech — 2019 filings

All 45 regulatory filings released by Active Biotech (ACTI) in 2019, sourced directly from the official regulator.

45 Filings
2019 Period
2019 filings (45)
Filing Released Lang
Active Biotechs valberedning utsedd
AGM Information
2019-11-19 Swedish
Active Biotech's election committee appointed
AGM Information
2019-11-19 English
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-11-14 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-11-14 English
New preclinical data on naptumomab estafenatox will be presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting
Regulatory Filings
2019-11-05 English
Nya prekliniska data för naptumomab estafenatox kommer att presenteras vid Society for Immunotherapy of Cancer’s 34th Annual Meeting
Regulatory Filings
2019-11-05 Swedish
Active Biotech och NeoTX meddelar idag att den första patienten har doserats i fas 1b-studien av naptumomab estafenatox i kombination med durvalumab i solida tumörer
Regulatory Filings
2019-10-28 Swedish
Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors
Regulatory Filings
2019-10-28 English
Active Biotech och NeoTX meddelar idag att den första patienten har doserats i fas 1b-studien av naptumomab estafenatox i kombination med durvalumab i solida tumörer
Regulatory Filings
2019-10-28 Swedish
Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors
Regulatory Filings
2019-10-28 English
Active Biotech: New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders
Regulatory Filings
2019-09-23 English
Active Biotech: New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders
Regulatory Filings
2019-09-23 English
Active Biotech: Nya data från fas 2-studien LEGATO-HD med laquinimod i Huntingtons sjukdom presenteras på den internationella kongressen ”Parkinson’s disease and movement disorders”
Regulatory Filings
2019-09-23 Swedish
Active Biotech: New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders
Regulatory Filings
2019-09-23 English
Active Biotech: New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders
Regulatory Filings
2019-09-23 English
Active Biotech: New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders
Regulatory Filings
2019-09-23 English
Active Biotech: New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders
Regulatory Filings
2019-09-23 English
Active Biotech: Nya data från fas 2-studien LEGATO-HD med laquinimod i Huntingtons sjukdom presenteras på den internationella kongressen ”Parkinson’s disease and movement disorders”
Regulatory Filings
2019-09-23 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report H1 2019
2019-08-08 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report H1 2019
2019-08-08 English
Annual Report 2018
Annual Report FY 2018
2019-06-05 English
Årsstämma i Active Biotech AB
AGM Information
2019-05-23 Swedish
Annual General Meeting of Active Biotech AB
AGM Information
2019-05-23 English
The Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the scientific conference "American Academy of Neurology - AAN" in Philadelphia, PA, on May 6 2019
Regulatory Filings
2019-05-03 English
Fas 2-studien LEGATO-HD med laquinimod i Huntingtons sjukdom presenteras på den vetenskapliga konferensen "American Academy of Neurology - AAN" i Philadelphia, PA, den 6 maj, 2019
Regulatory Filings
2019-05-03 Swedish
Valberedningen i Active Biotech AB föreslår Michael Shalmi som ny styrelseordförande och Uli Hacksell som ny ordinarie styrelseledamot
Board/Management Information
2019-05-02 Swedish
The Election Committee of Active Biotech AB proposes Michael Shalmi to be appointed new Chairman of the Board and Uli Hacksell to be appointed new member of the Board
AGM Information
2019-05-02 English
Annual Report 2018
Annual Report FY 2018
2019-04-26 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-04-25 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-04-25 English
Active Biotech: KALLELSE TILL ÅRSSTÄMMA
AGM Information
2019-04-24 Swedish
Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
AGM Information
2019-04-24 English
Active Biotech slutför fastighetsöverlåtelse
M&A Activity
2019-04-05 Swedish
Active Biotech completes sale of property
Regulatory Filings
2019-04-05 English
Extraordinary General Meeting of Active Biotech AB
AGM Information
2019-04-04 English
Extra bolagsstämma i Active Biotech
AGM Information
2019-04-04 Swedish
NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING OF ACTIVE BIOTECH AB (PUBL)
AGM Information
2019-03-13 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I ACTIVE BIOTECH AB (PUBL)
AGM Information
2019-03-13 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report FY 2018
2019-02-14 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report FY 2018
2019-02-14 English
Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study
Regulatory Filings
2019-02-11 English
Active Biotechs partner NeoTX inleder samarbete med AstraZeneca för att utvärdera ANYARA i kombination med IMFINZI® (durvalumab) i den planerade fas 1b/2 studien
Regulatory Filings
2019-02-11 Swedish
Active Biotech has received an indicative bid for the property in Lund - the Board is positive
Regulatory Filings
2019-02-01 English
Active Biotech har erhållit indikativt bud på fastigheten i Lund - styrelsen är positiv
M&A Activity
2019-02-01 Swedish
Major Shareholding Notification 2019
Major Shareholding Notification
2019-01-08 English